Comprehensive genomic profiling of clinically relevant cancer genes with Illumina’s TruSight Oncology 500 (TSO 500) NGS assay
The TSO 500 portfolio consists of two assays which enable precision oncology through pan-cancer comprehensive
genomic profiling (CGP) for solid tumors from either blood or tissue biopsy samples.
